CN104878125B - 一种针对乙型肝炎病毒多耐药位点的高通量检测方法 - Google Patents
一种针对乙型肝炎病毒多耐药位点的高通量检测方法 Download PDFInfo
- Publication number
- CN104878125B CN104878125B CN201510341871.4A CN201510341871A CN104878125B CN 104878125 B CN104878125 B CN 104878125B CN 201510341871 A CN201510341871 A CN 201510341871A CN 104878125 B CN104878125 B CN 104878125B
- Authority
- CN
- China
- Prior art keywords
- pcr
- primer
- virus
- hepatitis type
- detection method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 30
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title claims abstract description 21
- 238000001514 detection method Methods 0.000 title claims abstract description 20
- 238000012163 sequencing technique Methods 0.000 claims abstract description 40
- 238000012408 PCR amplification Methods 0.000 claims abstract description 18
- 230000035772 mutation Effects 0.000 claims abstract description 15
- 238000007405 data analysis Methods 0.000 claims abstract description 10
- 238000007689 inspection Methods 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 8
- 238000002493 microarray Methods 0.000 claims description 6
- 230000000869 mutational effect Effects 0.000 claims description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 10
- 230000004907 flux Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 20
- 239000000203 mixture Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Abstract
Description
上游标签序列 | 下游标签序列 |
ACA | AGT |
ACG | AGA |
TAC | TGC |
TAG | TGA |
CAT | CTG |
ATC | ACT |
ATG | AGC |
TCA | TGT |
TCG | CGT |
CAG | CGC |
CTA | CAC |
ACA | AGT |
ACG | AGA |
成分 | 体积(μl) |
DNA | 5 |
2×Gold Star Master Mix | 10 |
1μM F | 1 |
1μM R | 1 |
DNase-Free water | 3 |
成分 | 体积(μl) |
DNA | 20 |
TrueSeq Universal Primer(1μl) | 1.25 |
TrueSeq Primer-Index4(1μl) | 1.25 |
2×HiFi PCR Master Mix | 25 |
Water | 2.5 |
总体系 | 50 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510341871.4A CN104878125B (zh) | 2015-06-18 | 2015-06-18 | 一种针对乙型肝炎病毒多耐药位点的高通量检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510341871.4A CN104878125B (zh) | 2015-06-18 | 2015-06-18 | 一种针对乙型肝炎病毒多耐药位点的高通量检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104878125A CN104878125A (zh) | 2015-09-02 |
CN104878125B true CN104878125B (zh) | 2017-11-07 |
Family
ID=53945798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510341871.4A Active CN104878125B (zh) | 2015-06-18 | 2015-06-18 | 一种针对乙型肝炎病毒多耐药位点的高通量检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104878125B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107236788B (zh) * | 2016-03-29 | 2021-07-02 | 杭州致远医学检验所有限公司 | 一种非诊断目的的检测幽门螺杆菌基因及药物代谢型的Miseq测序方法 |
CN107236787A (zh) * | 2016-03-29 | 2017-10-10 | 杭州致远医学检验所有限公司 | 一种基于pgm高通量测序技术指导幽门螺杆菌根除用药的方法 |
CN110714095A (zh) * | 2018-07-12 | 2020-01-21 | 上海欧易生物医学科技有限公司 | 一种基于长片段测序检测hiv耐药位点突变序列多样性的方法 |
CN111073998A (zh) * | 2018-10-19 | 2020-04-28 | 深圳华大生命科学研究院 | 病毒基因组突变检测方法、装置和存储介质 |
CN109609694B (zh) * | 2018-12-29 | 2022-03-01 | 上海昂朴生物科技有限公司 | 基于Illumina测序技术检测乙型肝炎分型及多耐药位点的试剂盒及方法 |
CN109628568A (zh) * | 2019-01-10 | 2019-04-16 | 上海境象生物科技有限公司 | 一种用于判别和校准高通量测序污染的内标及其应用 |
CN111041069B (zh) * | 2019-12-26 | 2021-01-19 | 人和未来生物科技(长沙)有限公司 | 一种低起始量dna样本的高通量测序文库构建方法及其应用 |
CN111778562A (zh) * | 2020-07-08 | 2020-10-16 | 复旦大学附属华山医院 | 一种用于获取颅颈动脉夹层致病基因突变相关信息的dna文库及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102181575A (zh) * | 2011-03-18 | 2011-09-14 | 中国科学院武汉病毒研究所 | 用于检测乙型肝炎病毒耐药突变位点的引物及方法 |
CN102286645A (zh) * | 2011-08-30 | 2011-12-21 | 解码(上海)生物医药科技有限公司 | 乙型肝炎病毒耐药基因突变的检测探针、检测试剂盒及其检测方法 |
WO2014171898A2 (en) * | 2013-04-17 | 2014-10-23 | Agency For Science, Technology And Research | Method for generating extended sequence reads |
-
2015
- 2015-06-18 CN CN201510341871.4A patent/CN104878125B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102181575A (zh) * | 2011-03-18 | 2011-09-14 | 中国科学院武汉病毒研究所 | 用于检测乙型肝炎病毒耐药突变位点的引物及方法 |
CN102286645A (zh) * | 2011-08-30 | 2011-12-21 | 解码(上海)生物医药科技有限公司 | 乙型肝炎病毒耐药基因突变的检测探针、检测试剂盒及其检测方法 |
WO2014171898A2 (en) * | 2013-04-17 | 2014-10-23 | Agency For Science, Technology And Research | Method for generating extended sequence reads |
Non-Patent Citations (3)
Title |
---|
Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing;Ko SY et al.;《Clin microbiol infect》;20120601;第18卷(第10期);摘要,患者和方法,结果和讨论 * |
Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing;Han YX et al.;《Journal of virological methods》;20130414;第193卷(第2期);摘要,方法和结果,表1 * |
乙型肝炎病毒耐药变异及其检测研究进展;王洁等;《现代医药卫生》;20141230;第30卷(第24期);第3711-3713页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104878125A (zh) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104878125B (zh) | 一种针对乙型肝炎病毒多耐药位点的高通量检测方法 | |
EP3068883B1 (en) | Compositions and methods for identification of a duplicate sequencing read | |
CN108893466A (zh) | 测序接头、测序接头组和超低频突变的检测方法 | |
US20220348998A1 (en) | Methods for labelling nucleic acids | |
CN108026524A (zh) | 用于核酸文库标准化的方法和组合物 | |
CN106497920A (zh) | 一种用于非小细胞肺癌基因突变检测的文库构建方法及试剂盒 | |
CN107075581A (zh) | 由靶向测序进行数字测量 | |
CN105861487A (zh) | 用于靶向核酸序列富集和高效文库产生的组合物和方法 | |
CN106676182A (zh) | 一种低频率基因融合的检测方法及装置 | |
CN108753954B (zh) | 痴呆相关基因的捕获探针组、试剂盒、文库构建方法和用途 | |
CN102333890B (zh) | 使用编码的微载体进行的基因组选择和测序 | |
EP3536803A1 (en) | Quantitative cluster analysis method of target protein by using next-generation sequencing and use thereof | |
JP7134186B2 (ja) | Rnaおよびdnaからの核酸ライブラリーの作製 | |
CN103998625B (zh) | 用于病毒检测的方法和系统 | |
CN110468211A (zh) | 膀胱癌肿瘤突变基因特异性引物、试剂盒和文库构建方法 | |
JP5926189B2 (ja) | Rna分析方法 | |
CN102952895B (zh) | 一种利用测序技术检测未知病毒的方法 | |
CN114807300A (zh) | 单引物多重扩增技术在检测片段化稀有特征核酸分子中的应用及试剂盒 | |
CN107164365B (zh) | 应用三代测序技术检测染色体端粒dna全长的方法 | |
CN107406891A (zh) | Pcr方法 | |
CN108130366A (zh) | 一种构建人miRNA测序文库进行高通量测序的方法 | |
JP7152599B2 (ja) | 塩基配列決定のためのモジュール式およびコンビナトリアル核酸試料調製のためのシステムおよび方法 | |
CN103667267A (zh) | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 | |
CN106755505A (zh) | 用于检测血浆ctDNA中基因变异的试剂盒 | |
CN103667268A (zh) | 用于与braf基因杂交的dna探针库及采用其富集braf基因片段的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Xilu Inventor after: Chen Jing Inventor before: Wang Xilu Inventor before: Wu Qihan Inventor before: Dou Tonghai Inventor before: Chen Jing Inventor before: Xu Minjie |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150902 Assignee: Hangzhou Rongli Medicine Science &. Technology Co., Ltd. Assignor: Ang Piao bio tech ltd, Shanghai Contract record no.: 2017320010046 Denomination of invention: High throughput testing method of multiple drug-resisting sites of hepatitis B virus Granted publication date: 20171107 License type: Common License Record date: 20171221 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Xilu Inventor after: Gao Chunfang Inventor after: Chen Jing Inventor after: Jia Jianan Inventor before: Wang Xilu Inventor before: Chen Jing |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181107 Address after: 201100 D405 fourth, level 245, new Chun Ring Road, Minhang District, Shanghai. Co-patentee after: Dongfang Liver and Gall Surgery Hospital Patentee after: Ang Piao bio tech ltd, Shanghai Address before: 201100 D405 4, level 245, new Chun Ring Road, Minhang District, Shanghai. Patentee before: Ang Piao bio tech ltd, Shanghai |
|
TR01 | Transfer of patent right |